Eg5 Antibody (A-1): sc-365681

Eg5 Antibody (A-1) is a mouse monoclonal IgG1 antibody that detects KIF11 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-KIF11 antibody (A-1) targets KIF11, a crucial microtubule-based motor protein belonging to the BimC kinesin family, which plays a vital role in bipolar spindle formation during eukaryotic cell division. KIF11 monoclonal antibody (A-1) recognizes a protein essential for accurate chromosome segregation, as KIF11 inhibition leads to mitotic arrest with monoastral microtubule arrays, ultimately affecting cell proliferation and tissue homeostasis. KIF11 is primarily located in the cytoplasm, where KIF11 interacts with microtubules to facilitate cellular component movement and ensure correct mitotic spindle assembly. Additionally, KIF11 undergoes post-translational modifications, including phosphorylation on serine residues during S phase and on both serine and threonine 927 during mitosis, which are critical for regulating spindle apparatus association, particularly during early prophase. Furthermore, KIF11 interacts with thyroid hormone receptor in the presence of thyroid hormone, linking KIF11 function to hormonal signaling pathways that influence cell division and differentiation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Eg5 Antibody (A-1) References:

1. Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphedema, and chorioretinal dysplasia caused by KIF11 mutations.  |  Robitaille, JM., et al. 2014. JAMA Ophthalmol. 132: 1393-9. PMID: 25124931
2. Identification of novel KIF11 mutations in patients with familial exudative vitreoretinopathy and a phenotypic analysis.  |  Li, JK., et al. 2016. Sci Rep. 6: 26564. PMID: 27212378
3. TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability.  |  Venuto, S., et al. 2020. Cancer Lett. 473: 98-106. PMID: 31904480
4. The oral KIF11 inhibitor 4sc-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.  |  Masanas, M., et al. 2021. Clin Transl Med. 11: e533. PMID: 34709738
5. ASPM promotes migration and invasion of anaplastic thyroid carcinoma by stabilizing KIF11.  |  Fang, Q., et al. 2023. Cell Biol Int. 47: 1209-1221. PMID: 36883909
6. Cyclovirobuxine D inhibits growth and progression of non‑small cell lung cancer cells by suppressing the KIF11‑CDC25C‑CDK1‑CyclinB1 G2/M phase transition regulatory network and the NFκB/JNK signaling pathway.  |  Xue, T., et al. 2023. Int J Oncol. 62: PMID: 36929198
7. HELLS Knockdown Inhibits the Malignant Progression of Lung Adenocarcinoma Via Blocking Akt/CREB Pathway by Downregulating KIF11.  |  Yang, G., et al. 2025. Mol Biotechnol. 67: 548-561. PMID: 38478260
8. Transport of Golgi-localized β-catenin p-S47 by KIF11 or KIFC3 induces primary ciliogenesis.  |  Lee, NY., et al. 2024. Mol Cells. 47: 100142. PMID: 39476973
9. High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression.  |  Wu, Z., et al. 2025. J Transl Med. 23: 66. PMID: 39810156
10. Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma.  |  Cheng, X., et al. 2025. J Transl Med. 23: 197. PMID: 39966857

The preferred Eg5 antibody is Eg5 Antibody (F-1): sc-374212.